$2.91 Earnings Per Share Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter

Equities research analysts expect that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will report earnings per share of $2.91 for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Jazz Pharmaceuticals’ earnings. The highest EPS estimate is $3.04 and the lowest is $2.83. Jazz Pharmaceuticals reported earnings of $2.95 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 1.4%. The business is scheduled to report its next quarterly earnings report on Tuesday, February 26th.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year earnings of $12.98 per share for the current year, with EPS estimates ranging from $12.89 to $13.10. For the next financial year, analysts forecast that the company will report earnings of $13.82 per share, with EPS estimates ranging from $13.05 to $14.78. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.32 by $0.26. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The company had revenue of $469.37 million during the quarter, compared to analysts’ expectations of $482.64 million. During the same period last year, the company posted $3.22 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 14.0% on a year-over-year basis.

JAZZ has been the subject of several research reports. Piper Jaffray Companies set a $213.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, October 19th. Stifel Nicolaus increased their price objective on shares of Jazz Pharmaceuticals from $180.00 to $205.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Seaport Global Securities reiterated a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 9th. Wells Fargo & Co reiterated a “buy” rating and set a $195.00 price objective (up previously from $182.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 15th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $201.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, November 6th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Jazz Pharmaceuticals has an average rating of “Buy” and a consensus target price of $189.76.

JAZZ stock traded down $1.15 during trading on Friday, hitting $143.50. 1,114,128 shares of the company’s stock traded hands, compared to its average volume of 522,401. Jazz Pharmaceuticals has a 52 week low of $130.15 and a 52 week high of $184.00. The company has a quick ratio of 4.16, a current ratio of 4.29 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $8.73 billion, a P/E ratio of 15.01, a price-to-earnings-growth ratio of 0.87 and a beta of 0.94.

In other news, CEO Bruce C. Cozadd sold 1,300 shares of the firm’s stock in a transaction dated Friday, September 21st. The shares were sold at an average price of $164.36, for a total value of $213,668.00. Following the completion of the sale, the chief executive officer now owns 281,215 shares in the company, valued at approximately $46,220,497.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Matthew P. Young sold 700 shares of the firm’s stock in a transaction dated Friday, November 23rd. The stock was sold at an average price of $150.00, for a total transaction of $105,000.00. Following the completion of the sale, the chief financial officer now owns 32,068 shares of the company’s stock, valued at approximately $4,810,200. The disclosure for this sale can be found here. Insiders sold a total of 6,600 shares of company stock valued at $1,063,472 in the last 90 days. Company insiders own 3.90% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in JAZZ. Aperio Group LLC increased its holdings in shares of Jazz Pharmaceuticals by 19.3% during the 2nd quarter. Aperio Group LLC now owns 11,069 shares of the specialty pharmaceutical company’s stock valued at $1,907,000 after acquiring an additional 1,787 shares during the last quarter. Tdam USA Inc. increased its holdings in shares of Jazz Pharmaceuticals by 14.8% during the 2nd quarter. Tdam USA Inc. now owns 2,818 shares of the specialty pharmaceutical company’s stock valued at $486,000 after acquiring an additional 363 shares during the last quarter. TD Asset Management Inc. increased its holdings in shares of Jazz Pharmaceuticals by 9.1% during the 2nd quarter. TD Asset Management Inc. now owns 51,612 shares of the specialty pharmaceutical company’s stock valued at $8,892,000 after acquiring an additional 4,321 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $429,000. Finally, Comerica Bank acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $436,000. Hedge funds and other institutional investors own 91.53% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: Investing in Growth Stocks

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply